We are live on ! Find out more
CLVS

Clovis Oncology, Inc.

Delisted

CLVS was delisted on the 20th of December, 2022.

138 hedge funds and large institutions have $1.31B invested in Clovis Oncology, Inc. in 2014 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 58 increasing their positions, 38 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more funds holding in top 10

Funds holding in top 10: 47 (+3)

53% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 38

26% more call options, than puts

Call options by funds: $31M | Put options by funds: $24.6M

13% more capital invested

Capital invested by funds: $1.16B → $1.31B (+$147M)

8% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 25

1% less funds holding

Funds holding: 140138 (-2)

Holders
138
Holders Change
-2
Holders Change %
-1.43%
% of All Funds
4%
Holding in Top 10
7
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+75%
% of All Funds
0.2%
New
23
Increased
58
Reduced
38
Closed
25
Calls
$31M
Puts
$24.6M
Net Calls
+$6.38M
Net Calls Change
+$17.3M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$167M -$46.5M -1,112,950 -23%
NMC
2
NEA Management Company
Maryland
$103M
O
3
OppenheimerFunds
New York
$80.6M +$24.2M +580,202 +48%
PAI
4
Palo Alto Investors
California
$78.1M +$33.7M +806,436 +88%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$65.5M +$15.4M +368,400 +34%
Vanguard Group
6
Vanguard Group
Pennsylvania
$61.2M +$287K +6,866 +0.5%
PHS
7
PFM Health Sciences
California
$57.6M +$34.5M +825,475 +186%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$57.5M -$1.45M -34,800 -3%
BFA
9
BlackRock Fund Advisors
California
$43.5M +$37.6K +899 +0.1%
CPCM
10
Clifton Park Capital Management
Delaware
$35.9M
VAM
11
Visium Asset Management
New York
$35.8M +$16.8K +402 +0.1%
RG
12
Redmile Group
California
$35.6M +$2.53M +60,643 +8%
BIT
13
BlackRock Institutional Trust
California
$33.9M -$761K -18,217 -2%
State Street
14
State Street
Massachusetts
$32.1M +$1.47M +35,124 +5%
PCM
15
Pentwater Capital Management
Florida
$29.5M +$3.02M +72,200 +12%
BB
16
BB Biotech
Switzerland
$25.3M
TCM
17
TimesSquare Capital Management
New York
$21.1M +$1.78M +42,710 +10%
ACH
18
ArrowMark Colorado Holdings
Colorado
$17.7M -$346K -8,283 -2%
RFC
19
Russell Frank Company
Washington
$15.6M +$9.17M +219,487 +177%
SCM
20
Suffolk Capital Management
New York
$15.5M +$5.49M +131,385 +62%
Goldman Sachs
21
Goldman Sachs
New York
$15.3M -$2.56M -61,164 -15%
BA
22
BlackRock Advisors
Delaware
$14.1M +$12.4M +296,363 +1,919%
Northern Trust
23
Northern Trust
Illinois
$13.5M +$1.55M +37,038 +14%
TCP
24
TAMRO Capital Partners
Virginia
$12.6M +$2.23M +53,461 +24%
HCMT
25
Highland Capital Management (Texas)
Texas
$12M +$11.1M +265,000 New

CLVS Hedge Fund Activity: Q3 2014 in Review

138 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q3 2014, worth a combined $1.31B — up 13% from $1.16B a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of CLVS and 23 opened new positions — a net loss of 2 holders — while 38 trimmed existing stakes and 58 added.

The largest buyer was PFM Health Sciences, adding an estimated $34.5M. The largest seller was Fidelity Investments, cutting an estimated $46.5M.

  • 138 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q3 2014, down from 140 in Q2 2014.
  • Funds reported $1.31B of Clovis Oncology, Inc. stock for Q3 2014, up 13% quarter-over-quarter.
  • 23 funds opened new Clovis Oncology, Inc. positions in Q3 2014 and 25 closed out, a net change of -2 holders.
  • The largest Clovis Oncology, Inc. buyer in Q3 2014 was PFM Health Sciences, an estimated $34.5M added.
  • The largest Clovis Oncology, Inc. seller in Q3 2014 was Fidelity Investments, an estimated $46.5M sold.

Based on aggregated 13F filings for Q3 2014.